Trial intelligence / Profile preview

ERCC1/RRM1-Based Adjuvant Therapy in Stage I NSCLC

NCT00792701Phase 2Completed

Sponsor
SWOG Cancer Research Network
Start
Nov 2008
Primary completion
Apr 2016
Modality
Nanoparticles, Small Molecules
Countries
1
01

Overview

A Phase 2 trial of Cisplatin micelle injection (HA132), gemcitabine in non-small cell lung cancer (NSCLC), sponsored by SWOG Cancer Research Network. Started Nov 2008; status: completed.

02

Drugs

Cisplatin micelle injection (HA132)gemcitabine
03

Conditions

non-small cell lung cancer (NSCLC)

Beyond the preview

Go deeper on NCT00792701.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00792701.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call